Plegridy 63/94mcg injection contains active components as pegylated Interferon Beta-1A. It  is a medication used to treat multiple sclerosis (MS). Multiple sclerosis is a chronic autoimmune disease of the central nervous system characterized by inflammation, demyelination, and a wide range of neurological symptoms. One of the primary benefits of this medication is its ability to reduce the frequency of relapses in individuals with relapsing forms of MS. This can lead to a more stable disease course.: Modulating the immune response and reducing inflammation may slow down the progression of disability in people with MS. This can help individuals maintain a higher level of functioning for a longer period. Individuals who have a known hypersensitivity or allergy to Pegylated Interferon Beta-1A or any of its components should not use this medication. Suppose a patient has a history of severe depression, significant mood disorders, or suicidal ideation. In that case, the use of this medication should be carefully considered as it can have neuropsychiatric side effects. It can affect liver function, and individuals with severe liver disease or liver dysfunction should not use this medication. Although it primarily undergoes hepatic metabolism (in the liver), it is also partially excreted through the kidneys. Patients with severe renal impairment may require dose adjustments or alternative treatments. The safety and effectiveness of plegridy 63/94mcg injection in pediatric patients have not been established, and it is generally not recommended for use in children.